Mandate

Vinge wins in the Swedish Supreme Court – Vinge acts as counsel in important case for the real estate sector

March 31, 2021 Dispute Resolution

The Swedish Supreme Court has delivered its judgment today in a case concerning the formal requirements in the Swedish Tenant-Owners Associations Act in connection with so-called preliminary agreements for newly produced tenant-owner properties.

The issue in the case related to how the statutory requirement relating to the “estimated date of the grant” should be construed. In its judgement, the Swedish Supreme Court stated that an estimated date for the grant can be specified as a time interval. The agreement in question specified a period of six months, which was thus deemed to fulfil the formal requirement according to the Swedish Tenant-Owners Associations Act. The Swedish Supreme Court’s judgement constitutes an important clarification for the real estate sector.

The successful tenant-owners’ association was advised by Vinge through advokat Cecilia Möller Norsted and advokat Philip Danielsson.

You can read the complete judgment here.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025